Source: International Congress 2015 – Advances in the future treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Naimish Patel (Waltham, United States of America), Naimish Patel, Danen Cunoosamy, Tove Hegelund-Myrback, Rikard Pehrson, Ziad Taib, Paul Jansson, Sofia Lundin, Steven Greenaway, Graham Clarke, Leonard Siew. AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans. Eur Respir J 2015; 46: Suppl. 59, 483

Member's Comments

No comment yet.

Related content which might interest you: PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Cryptotanshinone attenuates airway Inflammation induced by cigarette smoke in mice Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 New anti-inflammatory activities of Alpha-1-Antitrypsin and their role in COPD Source: Annual Congress 2005 - Protease-antiprotease revisited Year: 2005 Ceramide-1-phosphate attenuates cigarette smoke induce lung inflammation Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Quercetin attenuates inflammation in cigarette smoke stimulated airway epithelial cells: Possible involvement of autophagy Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016